Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.

Sophia FrentzasAnna Rachelle Austria MislangCharlotte LemechAdnan NagrialCraig UnderhillWenjing Wang Zhongmin Maxwell WangBaiyong LiYu XiaJermaine I G Coward

Published in: Journal for immunotherapy of cancer (2024)

NCT04047290.

Keyphrases